Trial Profile
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of Colony Stimulating Factor-1 Receptor, in Subjects with Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Edicotinib (Primary)
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms PRINCE
- Sponsors Provention Bio
- 28 Jan 2023 This trial has been completed in Poland (End Date: 13 Aug 2019) according to European Clinical Trials Database record.
- 14 Sep 2021 Status changed from active, no longer recruiting to completed.
- 28 May 2020 This trial has been completed in Poland (Global End Date: 13 Aug), according to European Clinical Trials Database record.